Skip to main content
OpenTrials
Completed

NCT Number: NCT03492086

Study of the Consumption of a Food Supplement in a Group of Healthy People

Bioactive supplements might display relevant therapeutic properties according to validated molecular effects. Herein, the effect of a supplement based on diterpenes from Rosmarinus Officinalis L. and alkylglycerols with proven properties against signaling pathways involved in tumorigenesis is evaluated. The biological and molecular effects of this supplement, mainly based on expected effects on immune and genetic modulatory properties is investigated. For this purpose, 60 healthy volunteers were enrolled in a six week, double-blind, randomized and parallel pilot study with two study arms -rosemary and alkylglycerol containing capsules and control capsules. The study includes the analysis of (1) immunological parameters (ex vivo cytokine profile of LPS stimulated PBMC and PBMC phenotyping by cluster differentiation (CD) markers), (2) regulation of the expression of genes linked to immuno-modulation, inflammation, oxidative stress response and cancer, and (3) the analysis of correlation of selected genetic variants (SNPs) with the differential responses among individuals.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Immune System and Related Disorders Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Viviana loria-Kohen

Madrid, 28049, Spain

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 55 years
  • Adequate understanding of the study.
  • Willingness to complete the entire treatment.

Exclusion criteria

  • BMI >30
  • Diagnosis of type 2 diabetes mellitus (T2D), hypertension, dyslipidemia or other cardiometabolic disorders
  • Impaired cognitive function;
  • Diagnosed hepatic, renal, or cardiovascular disease
  • Subjects with primary immunodeficiency disorders, consumption of drugs with influence on the immune system, splenectomy.
  • Presence of other pathologies like asthma, food allergies, Crohn's, myasthenia gravis, lupus
  • Consumption of vitamins, minerals, supplements of antioxidant extracts or protein supplements in the 2 weeks prior to the start of the study
  • Subjects treated with drugs affecting the lipid or glycemic profile during the previous 30 days
  • Consumption of anticoagulants or antiplatelet agents, cyclosporine, acetylsalicylic acid, antihistamines or sedatives
  • Hypersensitivity to rosemary, to its components or other members of the family of lipped plants or to soybean as excipient of the capsules
  • Allergy or hypersensitivity to fish
  • Habitual smoking or high consumption alcohol
  • Pregnant or lactating women
  • High-intensity physical exercise.

Treatment and study plan

Dietary supplementation with capsules containing rosemary and alkylglycerol

Dietary Supplement

Dietary supplementation with control capsules

Dietary Supplement

Primary outcomes

  1. Changes in ex vivo cytokine profile produced by lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs)

    Time frame: Baseline and after 6 weeks of treatment

    Isolated PBMCs were first incubated for 12h, and then after LPS treated. Supernatants were recovered to determine concentrations of Interleukin (IL) -1B, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFNy and TNFa using a magnetic bead-based immunoassay (Human High Sensitivity T Cell Magnetic Bead Panel A MAGPIX-Luminex) kit from Millipore, following the manufacturer's instructions. A minimum of 50 beads per parameter was analyzed by the MAGPIX-Luminex system. Raw data (median fluorescence intensity, MFI) were analyzed with the xPONENT software 4.1.

Secondary outcomes

  1. Changes in oxidative stress status

    Time frame: Baseline and after 6 weeks

    To evaluate the changes in the oxidative stress the following biomarkers were measured in urine samples:

    • Oxidized-low density lipoproteins measured by sandwich enzyme-linked immunosorbent assay (ELISA) by using the monoclonal antibody mAb-4E6 (Mercodia AB, Sweden)
    • Isoprostanes and thromboxane B2 quantified by competitive ELISA (Enzo Biochem, Inc., NY, USA and Oxford Biomedical Research, MI, USA, respectively).

  2. Changes in lipid profile

    Time frame: Baseline and after 6 weeks

    To evaluate lipid improvements the following measurements were considered: Triacylglycerol, Total Cholesterol, low Density Lipoprotein and High-Density Lipoprotein measured by routine laboratory (CQS, Madrid, Spain, which follows the UNE-ISO 15189:2007 directives) methods.

  3. Gene expression analysis

    Time frame: Baseline and after 6 weeks

    Gene-expression assays were performed in a HT-7900 Fast Real time PCR. GAPDH was used as endogenous control. RT-StatMiner software (Integromics® Inc., Madison, USA) was used to detect and determine the quality control and differential expression analyses. The Expression Suite Software (Life Technologies) program was used to obtain the Ct data. The ΔCt (Ct gene-CtGAPDH) was calculated and then the relative expression (RQ) between visits was calculated (V3-V1) following the 2-ΔΔCt method (Livak and Schmittgen 2001)

  4. DNA genotyping

    Time frame: Baseline

    Genotyping was performed using the QuantStudio 12 K Flex Real-Time PCR System (Life Technologies Inc., Carlsbad, CA) with a TaqMan OpenArray plates. Single nucleotide polymorphisms (SNPs) involved in different parts of the pathogenic processes of inflammation, immune system, obesity, lipid metabolism, redox homeostasis and cancer, were analyzed using TaqMan Genotyper software.

Sponsors and collaborators

Lead sponsor

IMDEA Food

Other

Registry information

Official study title

Clinical Study to Evaluate the Effectiveness and Safety of the Consumption of a Food Supplement in a Group of Healthy People

Acronym: FORCANCER

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Apr 10, 2018
Registry last updated
Apr 10, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.